Thursday, November 8, 2012

Qualcomm beats expectations


Qualcomm Inc. released its fourth quarter statements on November 7th.  The company’s fiscal fourth quarter ended September 30 and reported a profit growth of $1.27 billion, or 73 cents a share from $1.06 billion, or 62 cents a year. The reason for Qualcomm Inc.’s 20 percent profit growth was due to a rise in demand for chips in smartphones. Qualcomm also reported a revenues growth of 18% year-over-year to $4.87 billion. Net income was reported at $1.24 billion, up 20% year over year.  The operation income was reported at $1.24 billion, down 11% year over year.
The chairman and CEO of Qualcomm, Dr. Paul E. Jacobs released his statement saying ““I am very pleased with our performance this year. We delivered record revenues, earnings and MSM chipset shipments driven by increasing global consumption of wireless data across a diverse range of devices, particularly smartphones, As we continue to invest in and execute on our strategic priorities, our broad licensing program and industry-leading Snapdragon and 3G/LTE chipset roadmap position us for double-digit revenue growth again in fiscal 2013.”

The fiscal revenues of 2012 were reported at $19.12 billion as a 28% increase and the net income was reported at $6.11 billion as a 13% increase. The Diluted earnings per share were reported up 39% to $3.51 per share. The return of capital to stockholders were reported at $6 billion, up 22%, and consisted of 31% of revenues.

For the first quarter of the 2013 fiscal year the company expects an adjusted per-share profit of $1.08 to $1.16, with revenue of $5.6 billion to $6.1 billion.  The company estimates for the fiscal year of 2013 that revenues will increase from  the fiscal year results of 2012 of $19.12 billion to anywhere between $23 billion to $24 billion. They also expect that GAAP operating income will increase 16-25% for the fiscal year of 2013. The earnings per-shares expectations are between $4.12 to $4.32 a share for the upcoming fiscal year.
Shares jumped 7.7% after-hours to $62.60 after the company released its earnings and expectations. The stock is up 6.3% so far this year.

-Kristen Pfaffe, Junior analyst

Tuesday, November 6, 2012

Neustar (NSR) 3Q12 Earnings


Neustar reported financial results for their fiscal year 2012 third quarter yesterday after the close. Diluted earnings per share increased 50% to $0.90 per share and total revenue for the quarter grew 38% to $211.2 million. The street was looking for EPS of $0.72 per share on revenues of 210.25 million. Shares of NSR have reacted favorably to yet another “beat and raise”, up ~6% mid-way through trading Tuesday.

The integration of TARGUSinfo, reported as Information Services (IS), continues to proceed extremely well. While only the back office has been fully integrated into the company and management did not expected to see revenue synergy until late 2013 or early 2014, revenue synergies are already being realized. Neustar is reaping the benefits of a single coherent sales operation platform they have just finished developing, allowing them to cross-sell and up-sell new and existing services. IS revenue totaled $42.3 million, representing an 11% sequential growth. We see the early success of the IS segment as a positive near-term catalyst for Neustar as it is showing strong early signs of being a significant contributor to the company’s overall business, further diversifying revenue mix.

Neustar continues to participate in the recompete process for the NPAC contract. President and CEO Lisa Hook believes that based on the three criteria the RFP uses to evaluate potential bidders, Neustar is “well-positioned to retain the contract to manage the impacts of any term that will begin in July 2015”. Neustar has been the NPAC administrator for the past 15 years building the world’s largest and most complex local number portability system.

The company repurchased 688k shares for approximately $25 million during the third quarter. Despite the share repurchase, cash, cash equivalents, and investments increased $34.2 million, to $269.2 million. 

Friday, November 2, 2012

Life Technologies 3rd Quarter Earnings Release


Life Technologies reported earnings on Thursday November 2nd, 2012 after the markets closed.  Revenues came in at $911 million, coming in above the high range they provided in July of $900-$910 million, while non-GAAP EPS came in $0.92. Analysts’ estimates were at $0.89 prior to the earnings release, and the stock reacted favorably after the release. Their beat on prior estimates were driven mainly by a significant increase in sales of the Ion Proton platform, continued strong growth in emerging markets, and lower R&D spending.

Excluding currency headwinds, they managed to stay inline with estimates with growth in the US and Europe, grew 10% in Asia-Pacific, and 4% in a flat Japanese economy. Gross margins in the third quarter came in at 65.6%, approximately 50 basis points lower than the same period in 2011. Operating margins were 28% in the third quarter representing a 1.4% decrease year over year, mainly due to unfavorable currency rates and greater investments in Asia-Pacific and their medical and diagnostics business.

Life continues to face unfavorable currency exchange rates and uncertainty in academic funding in US and Europe, especially with the upcoming election and the fiscal cliff coming up. In spite of this, management has been proactive in making sure that they are prepared if things go sour for academic funding. They have outlined a strategic share-repurchasing program and continue to look for ways to pull back on discretionary spending while still investing in up and coming markets and businesses, which should continue to offset these headwinds. In the case that the current favored candidate wins the election and congress reaches a deal, revenues could come in much higher for the fourth quarter than they expected.

In light of this, LIFE continues to increase revenues each quarter by utilizing both a product differentiation strategy and offering its new machines at a discount compared to their competitor Illumina, Inc. Currently, Illumina is the favored player in the up and coming genome sequencing market, because of slightly higher accuracy in their machine. Compared to Illumina, LIFE’s machine offers much lower test times at a lower cost, but still offering quality comparable to Illumina’s machine. We feel that these advantages, as well as a possible downturn in academic spending, will push customers to buy LIFE’s product over Illumina’s in the short to mid-term, since researchers will have to find good quality products at cheaper prices. Furthermore, LIFE is always updating and advancing the technology that will improve the accuracy of their machine.

The bull case for LIFE increasingly rests on their new machine, however, management expects that increased sales of their machine can further drive growth in their consumables business through existing clients. Through Ion Torrent, they can offer their broad array of services and tests that they are well known for. Management continues to invest in markets they believe will show significant growth and have raised the lower end of their year end EPS by $0.05 to $3.95-$4.00. 

HLF -5.1%

Herbalife Ltd. (HLF) dropped 5.1% on November 2, 2012 (S&P - 0.9%). Although no company-specific event contributed to the decline, investors may have interpreted Monday's +3% earnings surprise as a sign of weakness - HLF has beat the mean consensus EPS estimate by 14.3% on average over the previous 4 quarters. Despite this dip, we continue to believe that the growth of daily consumption distribution and will drive net sales, and infrastructure investment associated with the company's 'Seed to Feed' initiative will grow margins moving forward.

MET Q3 earnings


MetLife inc. (MET) released quarter three earnings on October 31st.

A loss of $984 million including $1.6 billion in goodwill impairment related to its retail annuity business as MET reduces its exposure to the risky product. CEO Steven Kandarian is targeting back offerings such as variable annuities by 12% by 2016. Variable annuity sales fell 46% year over year in a reflection of this plan moving forward.

Operating profit climbed to $1.32 a share from $0.91 just a year earlier beating street estimates by $0.04. Asian operating earnings rose 17% to 259 million while the America’s grew by 58% to $1.2 Billion.

Management gave no guidance on possible losses incurred by Hurricane Sandy. The market has responded negatively to the stock as they try to price in possible exposure to the storm.

MET continues to progress in its sale of MetLife to GE Capital. This quarter changes were made to the deal to shift regulatory oversight of the deal away from the FDIC. The sale is projected to be approved prior to a January deadline where MET would have to submit a new capital plan to the Federal Reserve. The sale of MetLife Bank is the largest short term driver for the stock as it would allow MetLife Inc. to raise the annual dividend and start share repurchasing programs. 

Thursday, November 1, 2012

HLF Q3

Herbalife Ltd. (HLF) released Q3 2012 results on Monday, October 29.

Net Sales of $1.0 billion (+14%) were driven by a 17% increase in volume points over the prior year period. A 100 bps decrease in EBIT margin (15.3%) during the quarter was due to FX headwinds. Net Income totalled $117.8 - a 9% increase over Q3 2011.

Q3 EPS of $1.04 beat the consensus estimate by $0.03 or 3%. EPS guidance for FY 2012 has been raised from $3.88 - $3.98 to $3.99 - 4.03. Management has also introduced full-year 2013 guidance of $4.40 - $4.55.

Regarding our thesis, the expansion of the daily consumption DMO among distributors has continued into Q3. HLF now estimates the number of nutrition clubs worldwide to be 43,000, representing an increase of 18% versus Q2. Daily consumption distribution methods now account for approximately 40% of total sales volume (vs. 37.5% in Q2). Additionally, the company continues to invest in infrastructure to support global growth. During Q3, HLF's board approved the construction of a $130 million East Coast (U.S.) manufacturing facility that management anticipates will be complete and operational in 2014.

Shares opened +4.6% when trading resumed Wednesday (October 31) morning.

Watson Pharmaceuticals (WPI) Q3 Earnings release


Watson Pharmaceuticals released its third quarter earnings this morning. This will be their last stand alone quarter before their Actavis acquisition will begin to shape their financial statements.

Net Revenue increased to $1.29 Billion based on several new Generic and Branded product debuts resulting in an increase of 19% versus prior year $1.08 Billion. By segment, Global Generics grew by 14% to $920.9 M, an increase of 118.4 M but $300 M shy of street estimates. Global Brands increased to ~10% to $121.3 M and Global Distribution increased significantly by 44% to $243 M versus last year’s $168.8 M. This increase was attributable to new third-party product launches during the third quarter

Total Operating expenses increased 27% to $1,196 B due to Increased marketing expenses from growing international sales, third-party costs in biosimilars, and other costs related to the Actavis Acquisition

Adjusted EBITDA saw a significant increase of 18% to $304.6 M versus 3Q 2011’s $258.2 M

Adjusted Net income showed a significant increase of 24.2% to $172.3 M. This resulted in $1.35 per diluted share on a non-gaap basis versus last year’s $1.09. This landed within the mid to upper end of analyst expectations.

Looking ahead, WPI estimates total net revenue for 2012 to be $5.9 Billion with adjusted non-gaap earnings between $5.85 and $5.95 per diluted share. Adjusted EBITDA should fall between $1.36 and $1.39 Billion

2013 non-GAAP EPS is expected to grow between 30% and 40% over the high end of the combined range of 2012. This is inclusive of an additional 5.5 Million shares outstanding at the close of the Actavis acquisition